Comparable stake leader
Leo Ehrlich
SEC ownership of Innovation Pharmaceuticals Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001355250.
Disclosed value leader
—
Comparable rows
0/4
Latest evidence
30 Dec 2022
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Leo Ehrlich
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
30 Dec 2022
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001355250
- Issuer location
- Wakefield, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Innovation Pharmaceuticals Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Leo Ehrlich
Disclosed value leader
—
Comparable rows
0/4
Latest evidence
30 Dec 2022
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
4 rows are not safely comparable across share classes.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 4 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Leo Ehrlich's linked filing trail.
Detailed SEC evidence table Showing 1-4 of 4 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Leo Ehrlich |
3/4/5
CEO and Chairman, Director
|
—
class O/S missing
|
—
4,333,936 shares
|
— | 30 Dec 2022 |
| Barry A. Schechter |
3/4/5
Director
|
—
mixed-class rows
|
—
1,750,000 shares
mixed-class rows
|
— | 23 Feb 2020 |
| Zorik Spektor |
3/4/5
Director
|
—
mixed-class rows
|
—
1,525,000 shares
mixed-class rows
|
— | 23 Feb 2020 |
| Jane A. Harness |
3/4/5
Vice President
|
—
mixed-class rows
|
—
744,417 shares
mixed-class rows
|
— | 01 Sep 2017 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 24 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-4 of 4 reporting-owner rows connected to Innovation Pharmaceuticals Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
4
Largest Forms 3/4/5 holder
Jane A. Harness
Net 12M change
$0
Latest report
30 Dec 2022
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jane A. Harness | Vice President | Mixed | 01 Sep 2017 | |||
| Barry A. Schechter | Director | Mixed | 23 Feb 2020 | |||
| Leo Ehrlich | CEO and Chairman, Director | Mixed | 30 Dec 2022 | |||
| Zorik Spektor | Director | Mixed | 23 Feb 2020 |
Recent insider transactions for Innovation Pharmaceuticals Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.